Patient Perceptions of Quality of Life With Diabetes-Related Complications and Treatments
暂无分享,去创建一个
David O. Meltzer | Elbert S. Huang | D. Meltzer | E. Huang | B. Ewigman | Sydney E. S. Brown | Bernard Ewigman | Edward Foley | Edward Foley
[1] Philip D. Harvey,et al. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38 , 1998, BMJ.
[2] D. Ronis,et al. BRIEF REPORT: The burden of diabetes therapy , 2005, Journal of General Internal Medicine.
[3] G. Naglie,et al. Quality of life of stroke in younger individuals. Utility assessment in patients with arteriovenous malformations. , 1997, Stroke.
[4] N. Clark,et al. Standards of Medical Care in Diabetes: Response to Power , 2006 .
[5] L. Campeau. Letter: Grading of angina pectoris. , 1976, Circulation.
[6] M. Weinstein,et al. Preference-based measures in economic evaluation in health care. , 2000, Annual review of public health.
[7] S. Kaplan,et al. Foot infections in diabetic patients. Decision and cost-effectiveness analyses. , 1995, JAMA.
[8] Tammy O. Tengs,et al. One thousand health-related quality-of-life estimates. , 2000, Medical care.
[9] B. Gage,et al. Cost-effectiveness of preference-based antithrombotic therapy for patients with nonvalvular atrial fibrillation. , 1998, Stroke.
[10] G. Brown,et al. Utilities associated with diabetic retinopathy: results from a Canadian sample , 2003, The British journal of ophthalmology.
[11] G. Torrance,et al. Measurement of quality of life in end-stage renal disease: the time trade-off approach. , 1987, Clinical and investigative medicine. Medecine clinique et experimentale.
[12] M. Engelgau,et al. Improvements in Diabetes Processes of Care and Intermediate Outcomes: United States, 19882002 , 2006, Annals of Internal Medicine.
[13] David O Meltzer,et al. The impact of patient preferences on the cost-effectiveness of intensive glucose control in older patients with new-onset diabetes. , 2006, Diabetes care.
[14] Anke Richter,et al. Cost-effectiveness of intensive glycemic control, intensified hypertension control, and serum cholesterol level reduction for type 2 diabetes. , 2002, JAMA.
[15] R. Steinbrook. Facing the diabetes epidemic--mandatory reporting of glycosylated hemoglobin values in New York City. , 2006, The New England journal of medicine.
[16] R. Holman,et al. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. , 1998 .
[17] Oluf Pedersen,et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. , 2003, The New England journal of medicine.
[18] N J Wald,et al. A strategy to reduce cardiovascular disease by more than 80% , 2003, BMJ : British Medical Journal.
[19] Alastair Gray,et al. Estimating Utility Values for Health States of Type 2 Diabetic Patients Using the EQ-5D (UKPDS 62) , 2002, Medical decision making : an international journal of the Society for Medical Decision Making.
[20] K. Kriegstein,et al. Inhaled insulin for diabetes mellitus. , 2007 .
[21] M. Weinstein,et al. Identifying and Valuing Outcomes , 1996 .
[22] S. Folstein,et al. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. , 1975, Journal of psychiatric research.
[23] N. Santanello,et al. HMG CoA reductase inhibitors and quality of life. , 1993, JAMA.
[24] M. Engelgau,et al. Valuing health-related quality of life in diabetes. , 2002, Diabetes care.
[25] C. Mackenzie,et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. , 1987, Journal of chronic diseases.